Full text is available at the source.
Patient‐reported outcome results in patients with type 2 diabetes treated with once‐weekly dulaglutide: data from the AWARD phase III clinical trial programme
Patient-reported results for people with type 2 diabetes taking weekly dulaglutide from a phase III clinical trial
AI simplified
Abstract
Significant within-group changes from baseline to the primary time point were observed for several patient-reported outcome measures in the AWARD clinical trial programme for dulaglutide.
- Dulaglutide 1.5 mg showed significantly greater improvements in the Impact of Weight on Self-Perception score compared to insulin glargine.
- Both doses of dulaglutide led to significantly greater improvements in the Impact of Weight on Ability to Perform Physical Activities of Daily Living score.
- All subscales of the Diabetes Treatment Satisfaction Questionnaire showed significantly greater improvement with both dulaglutide doses compared to exenatide.
- Dulaglutide 1.5 mg resulted in significantly greater improvement on the Diabetes Treatment Satisfaction Questionnaire hyperglycaemia subscale compared to metformin.
- These findings suggest that dulaglutide may be beneficial in the treatment of type 2 diabetes.
AI simplified